Find Daridorexant manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

0

Canada

0

Australia

0

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Daridorexant, 1505484-82-1, Act-541468, Quviviq, Daridorexant [usan], Lmq24g57e9
Molecular Formula
C23H23ClN6O2
Molecular Weight
450.9  g/mol
InChI Key
NBGABHGMJVIVBW-QHCPKHFHSA-N
FDA UNII
LMQ24G57E9

Daridorexant
Nemorexant is under investigation in clinical trial NCT03101189 (A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects).
Daridorexant is an Orexin Receptor Antagonist. The mechanism of action of daridorexant is as an Orexin Receptor Antagonist.
1 2D Structure

Daridorexant

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone
2.1.2 InChI
InChI=1S/C23H23ClN6O2/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28)/t23-/m0/s1
2.1.3 InChI Key
NBGABHGMJVIVBW-QHCPKHFHSA-N
2.1.4 Canonical SMILES
CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl
2.1.5 Isomeric SMILES
CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl
2.2 Other Identifiers
2.2.1 UNII
LMQ24G57E9
2.3 Synonyms
2.3.1 MeSH Synonyms

1. ((s)-(2-(5-chloro-4-methyl-1h-benzo(d)imidazol-2-yl)-2-methylpyrrolidin-1-yl) (5 Methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone)

2. Act-541468

3. Daridorexant

4. Methanone, ((2s)-2-(6-chloro-7-methyl-1h-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2h-1,2,3-traizol-2-yl)phenyl)-

2.3.2 Depositor-Supplied Synonyms

1. Daridorexant

2. 1505484-82-1

3. Act-541468

4. Quviviq

5. Daridorexant [usan]

6. Lmq24g57e9

7. Act541468

8. [(2~{s})-2-(6-chloranyl-7-methyl-1~{h}-benzimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-methoxy-2-(1,2,3-triazol-2-yl)phenyl]methanone

9. [(2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone

10. [(2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl][5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone

11. Methanone, ((2s)-2-(6-chloro-7-methyl-1h-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)-

12. Nemorexant (former Name)

13. Daridorexant [inn]

14. Unii-lmq24g57e9

15. Daridorexant [who-dd]

16. Chembl4297590

17. Schembl16766318

18. Gtpl11648

19. Bdbm334973

20. Dtxsid701336356

21. Nemorexant; Act-541468

22. Who 10679

23. Us9732075, Example 5.36

24. At32805

25. Db15031

26. Hy-109095

27. Cs-0039396

28. Act 541468;act-541468

29. (2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

30. (s)-(2-(5-chloro-4-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5 Methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

31. (s)-2-(5-chloro-4-methyl-1h Benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl](5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

32. [(s)-2-(5-chloro-4-methyl-1h-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone

2.4 Create Date
2015-06-22
3 Chemical and Physical Properties
Molecular Weight 450.9 g/mol
Molecular Formula C23H23ClN6O2
XLogP34.1
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Exact Mass450.1571017 g/mol
Monoisotopic Mass450.1571017 g/mol
Topological Polar Surface Area88.9 Ų
Heavy Atom Count32
Formal Charge0
Complexity693
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.


5 Pharmacology and Biochemistry
5.1 FDA Pharmacological Classification
5.1.1 Active Moiety
DARIDOREXANT
5.1.2 FDA UNII
LMQ24G57E9
5.1.3 Pharmacological Classes
Orexin Receptor Antagonists [MoA]; Orexin Receptor Antagonist [EPC]
5.2 ATC Code

N05


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41227

Submission : 2025-01-20

Status : Active

Type : II

Moehs Iberica
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content

Daridorexant

About the Company : Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic Development Zone, Sh...

Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic Development Zone, Shandong Province, the company operates API pilot testing and production facilities meeting international standards. It runs 13 production lines for oral solid, oral liquid, and API manufacturing, and is expanding capabilities for injections, soft capsules, eye drops, topical medicines, and innovative drug R&D. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Shandong Loncom Pharmaceutical company banner

02

Inke S.A

Spain
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInke S.A: APIs manufacturing plant.

Flag Spain
Digital Content Digital Content

Daridorexant

About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...

Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse therapeutic areas, but mainly for use in Respiratory. Inke has been successfully inspected by every major global authority for a wide array of products (last inspection on behalf of US-FDA was in 2023). For the last two decades, the company has made strong strides to become a prestige provider of respiratory APIs for inhalation. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Inke Company Banner

03

FARMAK, a.s

Czech Republic
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFarmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

Flag Czech Republic
Digital Content Digital Content

Daridorexant

About the Company : Farmak, A.S. is a privately held chemical and pharmaceutical company based in the Czech Republic. It specializes in researching, developing and producing active pharmaceutical ingr...

Farmak, A.S. is a privately held chemical and pharmaceutical company based in the Czech Republic. It specializes in researching, developing and producing active pharmaceutical ingredients (APIs), intermediates and specialized chemicals. The company primarily focuses on exporting its products, with the main markets being the EU, USA, India, Japan and Latin America. Additionally, Farmak offers contract manufacturing and custom synthesis services through its R&D department to support the clients. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Farmak Company Banner

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Daridorexant

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content

Daridorexant

About the Company : Since 1962, MOEHS has produced high-quality Active Pharmaceutical Ingredients (APIs) for the global market. With decades of technical expertise, Moehs Group delivers pharmaceutical...

Since 1962, MOEHS has produced high-quality Active Pharmaceutical Ingredients (APIs) for the global market. With decades of technical expertise, Moehs Group delivers pharmaceutical, veterinary, agrochemical, nutraceutical, cosmetic, and fine chemical products. Our facilities meet the highest standards, including GMP, ICH, FDA, and TGA approvals, ensuring reliable and safe manufacturing. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only.
Moehs Iberica

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSupriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Flag India
Digital Content Digital Content

Daridorexant

About the Company : Supriya Lifescience Limited, established in 1987 and headquartered in Mumbai, is a globally recognized, technology-driven manufacturer of APIs, CDMO, and formulations. Its faciliti...

Supriya Lifescience Limited, established in 1987 and headquartered in Mumbai, is a globally recognized, technology-driven manufacturer of APIs, CDMO, and formulations. Its facilities in Lote and Ambernath are approved by USFDA, EUGMP, Health Canada, and other agencies. Specializing in antihistamines, antiallergics, vitamins, anesthetics, and anti-asthmatics, Supriya serves 1500+ customers in over 86 countries, with 15+ USDMFs, 10+ CEPs, and a 1050 KL manufacturing capacity. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Supriya
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more
  • Development Update

Details:

Daridorexant is a controlled substance drug, which is currently being evaluated in Phase IV clinical studies for the treatment of sleep initiation and maintenance disorders.


Lead Product(s): Daridorexant,Inapplicable

Therapeutic Area: Sleep Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Controlled Substance

Sponsor: Idorsia Pharmaceuticals

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 29, 2026

blank

01

Institut d'Investigació Biomèdica de Bellvitge

Country
arrow
PEGS Boston Summit
Not Confirmed

Institut d'Investigació Biomèdica de Bellvitge

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Daridorexant is a controlled substance drug, which is currently being evaluated in Phase IV clinical studies for the treatment of sleep initiation and maintenance disorders.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

April 29, 2026

blank
  • Development Update

Details:

Daridorexant is a controlled substance drug, which is currently being evaluated in Phase II clinical studies for the treatment of alcoholism.


Lead Product(s): Daridorexant,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Controlled Substance

Sponsor: National Institutes of Health

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 15, 2026

blank

02

Johns Hopkins University

Country
arrow
PEGS Boston Summit
Not Confirmed

Johns Hopkins University

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Daridorexant is a controlled substance drug, which is currently being evaluated in Phase II clinical studies for the treatment of alcoholism.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

April 15, 2026

blank

Details:

Through the licensing deal for Daridorexant, a controlled substance targeting the orexin receptor, the agreement aims to advance treatment options for insomnia.


Lead Product(s): Daridorexant,Inapplicable

Therapeutic Area: Sleep Brand Name: Quviviq

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Pharmalink, S.L.

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 10, 2026

blank

03

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Through the licensing deal for Daridorexant, a controlled substance targeting the orexin receptor, the agreement aims to advance treatment options for insomnia.

Product Name : Quviviq

Product Type : Controlled Substance

Upfront Cash : Undisclosed

March 10, 2026

blank

Details:

Through the licensing deal for Daridorexant, a controlled substance targeting the orexin receptor, the agreement aims to advance treatment options for insomnia.


Lead Product(s): Daridorexant,Inapplicable

Therapeutic Area: Sleep Brand Name: Quviviq

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: EMS

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 28, 2026

blank

04

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Through the licensing deal for Daridorexant, a controlled substance targeting the orexin receptor, the agreement aims to advance treatment options for insomnia.

Product Name : Quviviq

Product Type : Controlled Substance

Upfront Cash : Undisclosed

January 28, 2026

blank

Details:

Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.


Lead Product(s): Daridorexant,Inapplicable

Therapeutic Area: Sleep Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 19, 2025

blank

05

Nxera Pharma

Japan
arrow
PEGS Boston Summit
Not Confirmed

Nxera Pharma

Japan
arrow
PEGS Boston Summit
Not Confirmed

Details : Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

June 19, 2025

blank

Details:

Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Daridorexant,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 22, 2024

blank

06

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

March 22, 2024

blank

Details:

Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.


Lead Product(s): Daridorexant,Inapplicable

Therapeutic Area: Sleep Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 24, 2023

blank

07

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

August 24, 2023

blank

Details:

Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stress Disorders, Post-Traumatic.


Lead Product(s): Daridorexant,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Controlled Substance

Sponsor: U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 17, 2023

blank

08

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Daridorexant,Inapplicable

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stress Disorders, Post-Traumatic.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

July 17, 2023

blank
  • Development Update

Details:

Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.


Lead Product(s): Daridorexant,Inapplicable

Therapeutic Area: Neurology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Controlled Substance

Sponsor: Idorsia Pharmaceuticals

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 29, 2023

blank

09

University Hospital, Montpellier

Country
arrow
PEGS Boston Summit
Not Confirmed

University Hospital, Montpellier

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

June 29, 2023

blank

Details:

Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Daridorexant,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 26, 2023

blank

10

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Daridorexant is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

May 26, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 103146-25-4

End Use API : Daridorexant

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSupriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Daridorexant

Brand Name :

Dosage Form : Tablet

Dosage Strength : 25MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Supriya

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSupriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Daridorexant

Brand Name :

Dosage Form : Tablet

Dosage Strength : 50MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Supriya

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Daridorexantum

Brand Name : QUVIVIQ

Dosage Form : Film Coated Tablet

Dosage Strength : 25mg

Packaging :

Approval Date : 01/12/2022

Application Number : 68481

Regulatory Info : Allowed

Registration Country : Switzerland

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Daridorexantum

Brand Name : QUVIVIQ

Dosage Form : Film Coated Tablet

Dosage Strength : 50mg

Packaging :

Approval Date : 01/12/2022

Application Number : 68481

Regulatory Info : Allowed

Registration Country : Switzerland

blank

05

Country
PEGS Boston Summit
Not Confirmed
arrow

Country
arrow
PEGS Boston Summit
Not Confirmed

Daridorexant

Brand Name : Quviviq

Dosage Form : Film-Coated Tablet

Dosage Strength : 25mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

06

Country
PEGS Boston Summit
Not Confirmed
arrow

Country
arrow
PEGS Boston Summit
Not Confirmed

Daridorexant

Brand Name : Quviviq

Dosage Form : Film-Coated Tablet

Dosage Strength : 50mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Daridorexantum

Brand Name : QUVIVIQ

Dosage Form : Film Coated Tablet

Dosage Strength : 25mg

Packaging :

Approval Date : 01/12/2022

Application Number : 68481

Regulatory Info : Allowed

Registration Country : Switzerland

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Daridorexantum

Brand Name : QUVIVIQ

Dosage Form : Film Coated Tablet

Dosage Strength : 50mg

Packaging :

Approval Date : 01/12/2022

Application Number : 68481

Regulatory Info : Allowed

Registration Country : Switzerland

blank

03

Idorsia Pharmaceuticals Deutschland Gmbh

Country
PEGS Boston Summit
Not Confirmed
arrow

Idorsia Pharmaceuticals Deutschland Gmbh

Country
arrow
PEGS Boston Summit
Not Confirmed

Daridorexant

Brand Name : Quviviq

Dosage Form : Film-Coated Tablet

Dosage Strength : 25mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

04

Idorsia Pharmaceuticals Deutschland Gmbh

Country
PEGS Boston Summit
Not Confirmed
arrow

Idorsia Pharmaceuticals Deutschland Gmbh

Country
arrow
PEGS Boston Summit
Not Confirmed

Daridorexant

Brand Name : Quviviq

Dosage Form : Film-Coated Tablet

Dosage Strength : 50mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions
The first quarter (Q1) of 2025 witnessed an impressive surge in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA), signaling a robust expansion in pharmaceutical development activities, the looming threat of tariffs notwithstanding.A total of 339 Type II DMFs were submitted during this period, as opposed to 235 submissions in Q1 2024, marking an exceptional increase of 44.26 percent. PharmaCompass’ data suggests that this is a record high for any first quarter.Overall, 440 DMFs were submitted across all categories (Types II, III, IV, and V) during Q1 2025, compared to 353 in the same period last year — representing a 24.65 percent increase.India and China continued to dominate the DMF landscape. India led with 162 submissions in Q1 2025, posting a remarkable 51.4 percent increase over 107 submissions recorded in Q1 2024. China followed with 135 submissions, representing a 33.66 percent increase over the 101 filings in Q1 2024.Taiwan sprung a surprise as a distant third. It made 12 DMF submissions in Q1 2025, as opposed to just one in Q1 2024. Western countries like the US, Spain, Germany, and Italy have maintained relatively stable or declining submission rates. Only the Netherlands showed significant growth with four DMF submissions in Q1 2025, up from zero in Q1 2024. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available)Indian giants MSN, Aurobindo, Cipla, Dr Reddy’s lead record-breaking DMF surgeIndia lived up to its “pharmacy of the world” reputation with the highest DMF submissions. In fact, seven of the top eight companies in the DMF tally were headquartered in India. MSN Group, emerged as the unequivocal leader with 23 submissions in Q1 2025, as against 15 in Q1 2024. Aurobindo Pharma increased its DMF activity from seven submissions in Q1 2024 to 12 in Q1 2025. Alivus Life Sciences, formerly known as Glenmark, made a dramatic leap with eight submissions in Q1 2025, quadrupling its previous year’s count of just two. Cipla more than doubled its DMF submissions — from three in Q1 2024 to eight in Q1 2025.Dr. Reddy’s Laboratories, one of India’s largest generic drugmakers, filed seven DMF submissions. The company’s Q1 2025 DMF portfolio includes high-value molecules like deucravacitinib, finerenone, enzalutamide, niraparib tosylate monohydrate, tucatinib, and tizanidine hydrochloride.Dr. Reddy’s has also indicated that they are open to manufacturing in the US. Meanwhile, Hetero Drugs filed seven submissions while Lee Pharma recorded six in Q1 2025.Chinese manufacturer Jiangsu East-Mab Biomedical Technology also established a significant presence with six DMFs. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Semaglutide, finerenone see most DMF submissions; first-time filings surge 64%Semaglutide and finerenone emerged as the most documented molecules in Q1 2025, each garnering nine DMF submissions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized diabetes management and weight loss treatment, continues to attract significant manufacturer interest. Similarly, finerenone, a non-steroidal drug used in treating chronic kidney disease in type 2 diabetes patients, has garnered attention from manufacturers.Carfilzomib, used in multiple myeloma treatment, secured the third position with five DMF submissions. Deucravacitinib, a novel drug approved for moderate to severe plaque psoriasis, followed with four DMF submissions.There were several molecules with three DMF submissions each. Among them were tapinarof, a novel drug for psoriasis, and tirzepatide, a GLP-1/GIP receptor agonist that has shown remarkable efficacy in diabetes and weight management. During the quarter, 23 molecules received their inaugural DMF submissions. This number has risen by 64 percent since Q1 2024, when only 14 drugs saw their first DMF filings.In Q1 2025, these 23 first-time molecules collectively garnered 30 DMF submissions, with deucravacitinib emerging as the clear leader. Indian companies Dr. Reddy’s Laboratories and Cipla filed DMFs for this plaque psoriasis treatment as did Spain’s Curia and PMC Global.The Q1 2025 roster of first-time DMF filings include retatrutide (another GLP-1 receptor agonist), sotagliflozin, setmelanotide acetate, daridorexant, nusinersen, zavegepant, belzutifan, elacestrant dihydrochloride, selumetinib sulfate, sotorasib, atogepant, omadacycline tosylate, osilodrostat phosphate, ensifentrine, landiolol hydrochloride, maralixibat chloride, maribavir, methyl olivetolate, diazoxide choline, sparsentan, thinnertide, and vismodegib. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Our viewGiven Trump’s rhetoric around tariffs on imported drugs, the record-breaking DMF submissions in Q1 2025 sent out a strong message that the global pharmaceutical industry is willing to take on the complex geopolitical situation with resilience and strategic foresight.On a different note, the rise in DMF filings also indicate increased workload for the FDA staff, as also more inspections by the agency. It seems like more ‘laid off’ FDA employees will be asked to return to work in the coming days.

Impressions: 4731

https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions

#PharmaFlow by PHARMACOMPASS
15 May 2025

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for 1505484-82-1 / Daridorexant API manufacturers, exporters & distributors?

Daridorexant manufacturers, exporters & distributors 1

42

PharmaCompass offers a list of Daridorexant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Daridorexant manufacturer or Daridorexant supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Daridorexant manufacturer or Daridorexant supplier.

API | Excipient name

Daridorexant

Synonyms

1505484-82-1, Act-541468, Quviviq, Daridorexant [usan], Lmq24g57e9, Act541468

Cas Number

1505484-82-1

Unique Ingredient Identifier (UNII)

LMQ24G57E9

About Daridorexant

Nemorexant is under investigation in clinical trial NCT03101189 (A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects).

Daridorexant Manufacturers

A Daridorexant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Daridorexant, including repackagers and relabelers. The FDA regulates Daridorexant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Daridorexant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Daridorexant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Daridorexant Suppliers

A Daridorexant supplier is an individual or a company that provides Daridorexant active pharmaceutical ingredient (API) or Daridorexant finished formulations upon request. The Daridorexant suppliers may include Daridorexant API manufacturers, exporters, distributors and traders.

click here to find a list of Daridorexant suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Daridorexant USDMF

A Daridorexant DMF (Drug Master File) is a document detailing the whole manufacturing process of Daridorexant active pharmaceutical ingredient (API) in detail. Different forms of Daridorexant DMFs exist exist since differing nations have different regulations, such as Daridorexant USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Daridorexant DMF submitted to regulatory agencies in the US is known as a USDMF. Daridorexant USDMF includes data on Daridorexant's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Daridorexant USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Daridorexant suppliers with USDMF on PharmaCompass.

Daridorexant GMP

Daridorexant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Daridorexant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Daridorexant GMP manufacturer or Daridorexant GMP API supplier for your needs.

Daridorexant CoA

A Daridorexant CoA (Certificate of Analysis) is a formal document that attests to Daridorexant's compliance with Daridorexant specifications and serves as a tool for batch-level quality control.

Daridorexant CoA mostly includes findings from lab analyses of a specific batch. For each Daridorexant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Daridorexant may be tested according to a variety of international standards, such as European Pharmacopoeia (Daridorexant EP), Daridorexant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Daridorexant USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty